Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3J9XC
|
|||
| Drug Name |
Cemdisiran
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Haemolytic uraemic syndrome [ICD-11: 3A21.2; ICD-10: D59.3] | Phase 2 | [1] | |
| Paroxysmal nocturnal haemoglobinuria [ICD-11: 3A21.0; ICD-10: D59.5] | Phase 2 | [2] | ||
| Company |
Alnylam Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C5 messenger RNA (C5 mRNA) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03303313) A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02352493) A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.